From USFDA
Zydus has received final approval from the USFDA to market Desoximetasone Ointment USP, 0.25%. Desoximetasone Ointment is used in relief of the inflammatory and puritic manifestation of corticosteroid responsive dermatoses. The drug would be manufactured at the group's Topical manufacturing facility at Ahmedabad.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
